Alderley Park, 24 May 2022 – Blueberry Therapeutics are pleased to report significant progress in our Phase 2b European trial of BB2603 in onychomycosis (BBTAF202).
The COVID-19 pandemic led to operational challenges in all 3 participating countries (Germany, Poland and Czech Republic) – including a trial pause to ensure patient and site staff safety. Blueberry has worked creatively to implement strategies to boost patient numbers and minimise delays, including protocol changes and roll-out of a multi-media advertising campaign to increase awareness of clinical research in this area. These have required multiple regulatory submissions to notify or obtain approval from Ethics Committees and Competent Authorities. We are delighted to share that the final approval in this jigsaw has been received and recruitment is expected to complete in July 2022. The primary endpoint is expected 1Q23.
For more information about Blueberry Therapeutics please contact:
Dr Emma Leigh, Director of Communications
info@blueberrytherapeutics.com
About Blueberry Therapeutics
Blueberry Therapeutics is a pharmaceutical company focused on the discovery, development and commercialisation of high value medicines for the treatment of common dermatological conditions that will positively impact on treatment outcomes and improve patient quality of life.
Blueberry applies innovative technologies to improve the delivery of existing drugs through the skin and nail. This enables better efficacy, safety and patient compliance while reducing drug dosage and cost of goods. The Company has a de-risked portfolio of best-in-class [advanced stage] clinical and preclinical assets addressing high value and poorly served indications in dermatology, including onychomycosis (fungal nail infection), tinea pedis (athletes’ foot) and atopic dermatitis (eczema).